Whiteoak Capital Pharma and Healthcare Fund - Direct Plan - Growth vs ICICI Prudential Pharma Healthcare and Diagnostics (p.h.d) Fund Direct Plan Growth-Insured
NAV, returns and costs — not a recommendation.
 Whiteoak Capital Pharma and Healthcare Fund - Direct Plan - Growth |  ICICI Prudential Pharma Healthcare and Diagnostics (p.h.d) Fund Direct Plan Growth-Insured | |
|---|---|---|
| NAV | ₹17.579 | ₹46.95 |
| NAV date | 2026-08-18 | 2026-08-19 |
| 1 year | +21.86% | +7.93% |
| 3 year (p.a.) | +24.98% | +22.86% |
| 5 year (p.a.) | +24.98% | +16.84% |
| Expense ratio | 0.60% | 0.87% |
| Fund size | ₹664.02 Cr | ₹6,624.58 Cr |
| Risk | — | Very high |
| Category | Sectoral Pharma and Healthcare | Sectoral Pharma and Healthcare |
Past performance does not guarantee future returns. Mutual fund investments are subject to market risks.